title: Treatment, management, and monitoring of established rheumatoid arthritis.
authors.affiliation: Division of Rheumatology and Allergy, The Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Clifton O
authors.initials: CO
authors.lastname: Bingham
authors.forename: Martin M
authors.initials: MM
authors.lastname: Miner
mesh_terms: D000069594:Abatacept; D000068879:Adalimumab; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D015897:Comorbidity; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D006875:Hydrotherapy; D006886:Hydroxychloroquine / Q000627:therapeutic use; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011320:Primary Health Care; D011379:Prognosis; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab; D012720:Severity of Illness Index; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine; D000069283:Rituximab; D006886:Hydroxychloroquine; D000069594:Abatacept; D000069285:Infliximab; D000068879:Adalimumab; D000077339:Leflunomide; D000068800:Etanercept; D008727:Methotrexate